1. Home
  2. PIM vs KZIA Comparison

PIM vs KZIA Comparison

Compare PIM & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Putnam Master Intermediate Income Trust

PIM

Putnam Master Intermediate Income Trust

N/A

Current Price

$2.99

Market Cap

153.2M

Sector

Finance

ML Signal

N/A

Logo Kazia Therapeutics Limited

KZIA

Kazia Therapeutics Limited

N/A

Current Price

$5.36

Market Cap

125.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PIM
KZIA
Founded
1988
1994
Country
United States
Australia
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
153.2M
125.6M
IPO Year
N/A
2002

Fundamental Metrics

Financial Performance
Metric
PIM
KZIA
Price
$2.99
$5.36
Analyst Decision
Strong Buy
Analyst Count
0
9
Target Price
N/A
★ $27.22
AVG Volume (30 Days)
63.3K
★ 241.7K
Earning Date
01-01-0001
12-01-2026
Dividend Yield
★ 8.28%
N/A
EPS Growth
N/A
N/A
EPS
★ 0.05
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$258.04
P/E Ratio
$60.00
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.95
$4.86
52 Week High
$3.41
$17.40

Technical Indicators

Market Signals
Indicator
PIM
KZIA
Relative Strength Index (RSI) 40.94 28.38
Support Level $2.96 $4.86
Resistance Level $3.21 $14.85
Average True Range (ATR) 0.04 0.68
MACD -0.01 -0.16
Stochastic Oscillator 0.00 9.86

Price Performance

Historical Comparison
PIM
KZIA

About PIM Putnam Master Intermediate Income Trust

Putnam Master Intermediate Income Trust is a closed-end fund. Its investment objective is to provide high current income and relative stability of net asset value. The fund pursues its goal by investing in U.S. high-grade, high-yield, and international fixed-income securities with limited maturities. The fund's portfolio includes the United States Government and agency mortgage obligations; mortgage-backed securities; corporate bonds and notes, and foreign government and agency bonds and notes.

About KZIA Kazia Therapeutics Limited

Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.

Share on Social Networks: